Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Example
OnOne month after vaccination, OPA GMTs in the PCV13 group were statistically higher than those in the PPSV23 group for 8 of the 12 serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines and for serotype 6A, a serotype unique to PCV13.
Patients with chronic stable medical disorders such as diabetes mellitus, cardiovascular diseases and chronic pulmonary diseases had similar immune responses as the normal population. However, the sample size for such patients was small for the possibility of a statistical analysis.3-5
A study evaluated immune responses in older adults, who had been vaccinated with PPSV23 at least 5 years before enrolment in the study.1,2 These patients were vaccinated with either PCV13 or PPSV23. The comparison of immune responses observed is shown in the figure below.
OnOne month after vaccination, OPA GMTs in the PCV13 group were statistically higher than those in the PPSV23 group for 8 of the 12 serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines and for serotype 6A, a serotype unique to PCV13.
Patients with chronic stable medical disorders such as diabetes mellitus, cardiovascular diseases and chronic pulmonary diseases had similar immune responses as the normal population. However, the sample size for such patients was small for the possibility of a statistical analysis.3-5
A study evaluated immune responses in older adults, who had been vaccinated with PPSV23 at least 5 years before enrolment in the study.1,2 These patients were vaccinated with either PCV13 or PPSV23. The comparison of immune responses observed is shown in the figure below.
Example
Example
A study evaluated the immune responses in older adults, who were not exposed to PPSV23 previously (vaccine-naïve adults).1,2 The results for the OPA GMT ratios for individual serotypes (1 month after dose) are as shown in the figure below.1,2
One month after vaccination, OPA GMTs in the PCV13 group were statistically higher than those in the PPSV23 group for 8 of the 12 serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines and for serotype 6A, a serotype unique to PCV13.1
Patients with chronic stable medical disorders such as diabetes mellitus, cardiovascular diseases and chronic pulmonary diseases had similar immune responses as the normal population. However, the sample size for such patients was small for the possibility of a statistical analysis.3-5
A study evaluated immune responses in older adults, who had been vaccinated with PPSV23 at least 5 years before enrolment in the study.1,2 These patients were vaccinated with either PCV13 or PPSV23. The comparison of immune responses observed is shown in the figure below.
The immune responses observed on revaccination with Prevenar 13® (PCV13) in those who were previously vaccinated with PPSV23 were superior to those revaccinated with PPSV23, for 11 of the 13 serotypes, and non-inferior for all the 13 serotypes.1,2
This indicates that vaccination with Prevenar 13® (PCV13) in adults previously vaccinated with PPSV23 elicits superior responses as compared with revaccination with PPSV23. The US ACIP Adult Immunization Schedule also recommends the sequential use of conjugate and polysaccharide vaccines in certain risk conditions.6
ACIP, Advisory Committee on Immunization Practices; GMT, geometric mean titre; OPA, opsonophagocytosis assay; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; US, United States.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0661 July 2023
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.